Who are Propofol/Lidocaine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ketamine and propofol, Propofol and Alfentanil, Sedation Etomidate combined with propofol, Propofol + Alfentanil, Propofol + Remifentanyl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propofol-lidocaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Propofol/Lidocaine — Competitive Intelligence Brief

Propofol/Lidocaine (Propofol/Lidocaine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous anesthetic combination. Area: Anesthesiology.

marketed Intravenous anesthetic combination GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Propofol/Lidocaine (Propofol/Lidocaine) — NYU Langone Health. Propofol and lidocaine together provide rapid induction and maintenance of anesthesia with reduced pain on injection through synergistic central nervous system depression.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Propofol/Lidocaine TARGET	Propofol/Lidocaine	NYU Langone Health	marketed	Intravenous anesthetic combination	GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)
ketamine and propofol	ketamine and propofol	Ain Shams University	marketed	Intravenous anesthetic combination	NMDA receptor (ketamine); GABA-A receptor (propofol)
Propofol and Alfentanil	Propofol and Alfentanil	North District Hospital	marketed	Intravenous anesthetic combination (hypnotic + opioid)	GABA-A receptor (propofol); mu opioid receptor (alfentanil)
Sedation Etomidate combined with propofol	Sedation Etomidate combined with propofol	RenJi Hospital	marketed	Intravenous anesthetic combination	GABA-A receptor
Propofol + Alfentanil	Propofol + Alfentanil	Region Jönköping County	marketed	Intravenous anesthetic combination (hypnotic + opioid)	GABA-A receptor (propofol); mu-opioid receptor (alfentanil)
Propofol + Remifentanyl	Propofol + Remifentanyl	Azienda Ospedaliera San Gerardo di Monza	phase 3	Intravenous anesthetic combination (hypnotic + opioid)	GABA-A receptor (propofol); mu-opioid receptor (remifentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous anesthetic combination class)

Ain Shams University · 1 drug in this class
NYU Langone Health · 1 drug in this class
RenJi Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propofol/Lidocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/propofol-lidocaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab